Nursen Cetrez

Om mig
Publikationer
Populärvetenskap och samverkan

Om mig

Läkare
Projektsamordnare, Cell och genterapi (Grupp Evren Alici)
Vetenskaplig koordinator, NextGenNK kompetenscentrum
Marmara Universitet, Medicinska Fakulteten, Istanbul, Turkiet (2014-2021)

Artiklar

Article: RHEUMATOLOGY. 2025;64(8):4650-4658
Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab
Depascale R; Da Mutten R; Lindblom J; Cetrez N; Palazzo L; Iaccarino L; Doria A; Nikolopoulos D; Gatto M; Parodis I
Article: RHEUMATOLOGY. 2025;64(7):4257-4266
Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials
Grosso G; Giannopoulou N; Tsoi A; Cetrez N; Nikolopoulos D; Lindblom J; Parodis I
Article: AUTOIMMUNITY REVIEWS. 2025;24(7):103810
Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: A systematic literature review-based proposal
Parodis I; Cetrez N; Palazzo L; Alberton V; Anders H-J; Bajema IM; Costedoat-Chalumeau N; Malvar A; Rovin BH; Sanchez-Guerrero J; Zhao M-H; Weinmann-Menke J; Tektonidou MG; Houssiau FA
Article: RMD OPEN. 2025;11(2):e005444
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria
Parodis I; Lindblom J; Palazzo L; Cetrez N; Oon S; Ala H; van Vollenhoven RF; Morand E; Levitsky A; Nikpour M
Article: RHEUMATOLOGY ADVANCES IN PRACTICE. 2025;9(2):rkaf032
Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithms
Botto J; Cetrez N; Nikolopoulos D; Regardt M; Heintz E; Lindblom J; Parodis I
Article: LANCET RHEUMATOLOGY. 2024;6(11):e751-e761
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
Parodis I; Lindblom J; Levy RA; Zen M; Cetrez N; Gomez A; Oon S; Henning C; Khamashta M; Quasny HA; Chauhan D; Askanase A; van Vollenhoven R; Nikpour M
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(9):1679-1689
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Article: RHEUMATOLOGY. 2024;63(9):2494-2502
Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity
Nikolopoulos D; Cetrez N; Lindblom J; Palazzo L; Enman Y; Parodis I
Article: RHEUMATOLOGY. 2024;63(3):798-808
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Article: KIDNEY INTERNATIONAL REPORTS. 2023;8(9):1822-1830
Effect of Belimumab on Preventing de novo Renal Lupus Flares
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau FA; Sjowall C; Rovin BH
Journal article: BEHAVIOURAL BRAIN RESEARCH. 2021;397:112923
High intensity interval training protects from Post Traumatic Stress Disorder induced cognitive impairment
Koyuncuoglu T; Sevim H; Cetrez N; Meral Z; Gonenc B; Dertsiz EK; Akakin D; Yuksel M; Cakir OK

Alla övriga publikationer

Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:942-943
NOVEL IGG AND IGA AUTOANTIBODIES DIFFERENTIATING SYSTEMIC LUPUS ERYTHEMATOSUS FROM PRIMARY SJÖGREN'S SYNDROME AND SYSTEMIC SCLEROSIS
Parodis I; Nikolopoulos D; Lindblom J; Beretta L; Cetrez N; Peyper J; Barturen G; Jakobsson PJ; Alarcon-Riquelme M; Idborg H
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2025;83:942.1-94942
IGG AND IGA AUTOANTIBODIES AGAINST NOVEL ANTIGEN SPECIFICITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH DIFFERENTIAL UNDERLYING MECHANISMS HERALDING PROMISE FOR EARLY DIAGNOSIS
Parodis I; Nikolopoulos D; Lindblom J; Beretta L; Cetrez N; Peyper J; Barturen G; Jakobsson PJ; Alarcon-Riquelme M; Idborg H
Conference publication: BLOOD. 2024;144:3320
Outcomes of Relapsed and Refractory Multiple Myeloma with the Evolving Standard of Care
Luong V; Kashif M; Uttervall K; Bohlin A; Cetrez N; Afram G; Nahi H; Lund J; Alici E
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:1010-1011
OUTCOMES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH INTRAVENOUS OR SUBCUTANEOUS BELIMUMAB: A POST-HOC EFFICACY META-ANALYSIS BY BICLA CRITERIA
Parodis I; Lindblom J; Cetrez N; Palazzo L; Oon S; Ala H; Van Vollenhoven RF; Morand E; Levitsky A; Nikpour M
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:1007
UNSUPERVISED MACHINE LEARNING IDENTIFIES DISTINCT SYSTEMIC LUPUS ERYTHEMATOSUS PATIENT ENDOTYPES BASED ON B CELL PHENOTYPING AND AUTOANTIBODY PROFILES WITH DIFFERENTIAL RESPONSE TO BELIMUMAB
Depascale R; Cetrez N; Lindblom J; Iaccarino L; Doria A; Nikoloupolos D; Gatto M; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:1006-1007
BELIMUMAB EFFICACY IN MUCOCUTANEOUS SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE POST-HOC ANALYSIS INTEGRATING DATA FROM FIVE PHASE III RANDOMISED CONTROLLED TRIALS
Grosso G; Giannopoulou N; Tsoi A; Cetrez N; Nikolopoulos D; Lindblom J; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2024;83:1001-1002
POOR HEALTH-RELATED QUALITY OF LIFE DESPITE LOW DISEASE ACTIVITY OR REMISSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Nikpour M; Levitsky A; Strand V
Conference publication: 2024;:a59.1-a5a59
P23 Presence of anti-Sm autoantibodies is associated with abatement of attainability of LLDAS and DORIS remission in systemic lupus erythematosus
Lourenço MH; Cetrez N; Tsoi A; Lindblom J; Nikolopoulos D; Parodis I
Conference publication: 2024;:a58.2-a5a58
P22 Consistent benefits from belimumab irrespective of antiphospholipid autoantibody profile, yet not in the presence of lupus anticoagulant
Tsoi A; Lindblom J; Cetrez N; Parodis I
Conference publication: 2024;:a39-a40
O42 Patients with systemic lupus erythematosus experience poor health-related quality of life despite a low disease activity state or remission
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Nikpour M; Levitsky A; Strand V
Conference publication: 2024;:a28.2-a2a29
O28 Unveiling the impact of neuropsychiatric involvement in systemic lupus erythematosus on damage accrual
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: 2024;:a14-a15
O11 Unsupervised machine-learning identifies distinct clusters based on B cell phenotyping and autoantibody profiles in patients with systemic lupus erythematosus
Gatto M; Depascale R; Cetrez N; Lindblom J; Nikolopoulos D; Doria A; Parodis I
Conference publication: 2024;:a119.1-a1a119
P110 Impact of neuropsychiatric involvement on health-related quality of life in patients with systemic lupus erythematosus
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: 2024;:a86.1-a8a86
P62 Machine learning approaches for prediction of renal flares in systemic lupus erythematosus: knowledge-driven models outperformed data-driven models
Cetrez N; Lindblom J; Mutten RD; Nikolopoulos D; Parodis I
Conference publication: 2024;:a85.2-a8a86
P61 Harnessing machine learning to predict neuropsychiatric events in systemic lupus erythematosus
Cetrez N; Lindblom J; Mutten RD; Nikolopoulos D; Parodis I
Conference publication: 2024;:a36.2-a3a37
O39 Immune deposit resorption in per-protocol repeat kidney biopsy performed in patients with proliferative lupus nephritis
Cetrez N; Tamirou F; Nieuwland S; Aydin S; Parodis I; Houssiau FA
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:5067-5069
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Parodis I; Lindblom J; Levy RA; Zen M; Cetrez N; Gomez A; Oon S; Henning C; Khamashta M; Quasny HA; Chauhan D; Askanase A; van Vollenhoven R; Nikpour M
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:2880-2881
Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:2879-2880
Unveiling the Impact of Neuropsychiatric Involvement in Systemic Lupus Erythematosus on Damage Accrual
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:4580-4581
Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models
Cetrez N; Lindblom J; Da Mutten R; Nikolopoulos D; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:4596-4597
Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus
Da Mutten R; Cetrez N; Lindblom J; Oon S; Nikolopoulos D; Nikpour M; Parodis I
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2023;75:1081-1082
Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus
Cetrez N; Lindblom J; Da Mutten R; Nikolopoulos D; Parodis I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52:45
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase Ill clinical trials of belimumab
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2023;52:46
De novo renal flares in SLE patients treated for active extra renal disease within five phase Ill clinical trials of belimumab. Implications for revisiting belimumab dose
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau F; Sjowall C; Rovin B
Conference publication: 2023;:a51.1-a5a51
LSO-028 Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab
Parodis I; Lindblom J; Çetrez N; Palazzo L; Ala H; Houssiau F; Sjöwall C; Rovin B
Conference publication: 2023;:a149.1-a1a149
LP-170 Predictors of neuropsychiatric flares In Patients With Systemic Lupus Erythematosus: Results From Five Phase III clinical trials of belimumab
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:1088
PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2023;82:909-910
PREDICTORS OF DE NOVO RENAL FLARES IN SYSTEMIC LUPUS ERYTHEMATOSUS - TIME TO REVISIT BELIMUMAB DOSE FOR EXTRA-RENAL DISEASE? RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
Parodis I; Lindblom J; Cetrez N; Palazzo L; Ala H; Houssiau F; Sjowall C; Rovin BH
Visa fler

Om mig

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI